A Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp ® (Amgen) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis (CKD).
Conditions: Anemia; Chronic Kidney Disease Requiring Chronic Dialysis Intervention: Biological: Stimus (NNG-DEPO) Sponsors: Nanogen Pharmaceutical Biotechnology Joint Stock Company; Vietstar Biomedical Research; MEDPHASE CLINICAL RESEARCH CONSULTANT COMPANY LIMITED; CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING COMPANY LIMITED; MedProve Inc Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Aranesp | Biotechnology | Chronic Kidney Disease | Dialysis | Nanotechnology | Research | Study | Training | Universities & Medical Training | Urology & Nephrology